Form 8.3 - Xeris Pharmaceuticals, Inc.

LONDON--()-- 

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)

Millennium International Management LP

Company dealt in

Xeris Pharmaceuticals, Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

US98422L1070

Date of dealing

25th June 2021

2. INTERESTS AND SHORT POSITIONS

a. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

1,810,007

(2.727%)

 

1,115,075

(1.680%)

(2) Derivatives (other than options)

-

-

(3) Options and agreements to purchase/sell

-

-

Total

1,810,007

(2.727%)

 

1,115,075

(1.680%)

b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

Ap20

1. DEALINGS (Note 4)

a. Purchases and sales

 

Purchase/sale

 

Number of relevant securities

Price per unit (Note 5)

(USD)

Sale

5,395

4.81

Purchase

5,395

4.81

Sale

20

4.61

Sale

100

4.54

Sale

10

4.70

Sale

40

4.76

Sale

19

4.74

Sale

11

4.84

Sale

16

4.38

Sale

200

4.49

Sale

160

4.43

Sale

100

4.51

Sale

124

4.72

Sale

100

4.67

Sale

100

4.74

Sale

1,541

4.57

Sale

3

4.62

Sale

2,120

4.49

Sale

10,064

4.54

Sale

832

4.71

Sale

8,318

4.53

Sale

34,865

4.52

Sale

7,554

4.51

Sale

451

4.56

Sale

500

4.55

Sale

357

4.50

Sale

513

4.70

Sale

779

4.75

Sale

9,056

4.79

Sale

502

4.73

Sale

4,104

4.68

Sale

12,250

4.72

Sale

7,201

4.78

Sale

600

4.67

Sale

3,202

4.74

Sale

409

4.84

Sale

5,533

4.77

Sale

2,213

4.80

Sale

5,532

4.83

Sale

1,328

4.44

Sale

18

4.59

Sale

1,000

4.57

Sale

352

4.38

Sale

200

4.81

Sale

381

4.62

Sale

200

4.39

Sale

1,100

4.49

Sale

300

4.54

Sale

325

4.65

Sale

100

4.66

Sale

100

4.43

Sale

100

4.71

Sale

1,628

4.53

Sale

1,000

4.52

Sale

300

4.56

Sale

700

4.50

Sale

200

4.70

Sale

300

4.82

Sale

610

4.79

Sale

200

4.73

Sale

300

4.68

Sale

297

4.72

Sale

400

4.76

Sale

300

4.78

Sale

100

4.67

Sale

200

4.74

Sale

200

4.84

Sale

200

4.77

Sale

1,038

4.80

Sale

100

4.91

Sale

300

4.90

Sale

100

4.46

Sale

1,029

4.38

Sale

500

4.36

Purchase

3,729

4.63

Purchase

760,274

4.81

Purchase

600

4.71

Purchase

11,469

4.56

Purchase

600

4.75

Purchase

832

4.79

Purchase

200

4.73

Purchase

600

4.72

Purchase

900

4.78

Purchase

300

4.89

Purchase

382

4.67

Purchase

200

4.74

Purchase

100

4.84

Purchase

1,833

4.80

Purchase

400

4.86

Purchase

600

4.83

Purchase

700

4.87

Purchase

198

4.91

Purchase

2,055

4.85

Purchase

120

4.93

Purchase

133

4.92

Purchase

767

4.88

Purchase

1,470,308

4.81

Sale

1,319

4.57

Sale

194

4.63

Sale

11,414

4.81

Sale

5,008

4.62

Sale

282

4.64

Sale

501

4.48

Sale

213

4.61

Sale

850

4.54

Sale

268

4.69

Sale

355

4.60

Sale

832

4.66

Sale

147

4.71

Sale

2,463

4.53

Sale

911

4.47

Sale

150

4.52

Sale

6,927

4.56

Sale

100

4.55

Sale

400

4.50

Sale

75

4.70

Sale

33,532

4.75

Sale

700

4.58

Sale

900

4.79

Sale

4,100

4.73

Sale

100

4.68

Sale

2,592

4.72

Sale

1,552

4.76

Sale

2,294

4.78

Sale

333

4.89

Sale

1,778

4.74

Sale

30,766

4.77

Sale

5,082

4.80

Sale

400

4.86

Sale

771

4.83

Sale

200

4.91

Sale

1,200

4.85

Purchase

1

4.38

Purchase

16,479

4.81

Purchase

100

4.64

Purchase

135

4.54

Purchase

190

4.69

Purchase

150

4.60

Purchase

80

4.53

Purchase

120

4.52

Purchase

180

4.51

Purchase

30

4.56

Purchase

100

4.50

Purchase

333

4.79

Purchase

9

4.73

Purchase

297

4.72

Purchase

35

4.76

Purchase

44

4.78

Purchase

106

4.74

Purchase

6

4.80

Purchase

200

4.83

Purchase

19

4.87

Purchase

60

4.91

Purchase

2,746

4.81

b. Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit (GBP)

(Note 5)

 

 

 

 

i. Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

c. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure

28th June 2021

Contact name

Milos Naumovic

Telephone number

+44 203 650 8203

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 

Category Code: RET
Sequence Number: 740321
Time of Receipt (offset from UTC): 20210628T120738+0100

Contacts

Millennium Partners, L.P.

Contacts

Millennium Partners, L.P.